Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5903_Библиотеки_им_академика_М_И_Перельмана.pdf
product is isolated, reformulated, characterised, and stored for subsequent use. In the
NN
5
Simultaneous
second step, radiolabelling is performed to give access to the nal radiolabelled product. An alternative two-step approach involves pre-radiolabelling the chelate and then
performing the bioconjugation step using the radioactive intermediate. Although highly
successful, these two-step approaches have a number of disadvantages, including the
need to produce, isolate, characterise, and potentially store an intermediate product.
As an alternative, our group is exploring the possibility of combining the bioconjugation
and radiolabelling steps into a simultaneous, one-pot process using an emerging concept that combines photochemistry with radiochemistry (photoradiochemistry)[132, 133].
The approach involves a multicomponent reaction in which a photoactivatable chelate is
mixed with the radionuclide and the protein at the same time, and then irradiated with
ultraviolet light (Scheme11.4). Radiolabelling of ‘free’ chelates that are not bound to protein can typically be accomplished in just a few seconds or minutes due to the enhanced
rate of diusion of small molecules. At the same time, photochemical activation of a substrate containing an aryl azide group generates extremely reactive arylnitrene intermediates that rapidly isomerise and then undergo facile and chemoselective reactions with
primary amines (lysine residues). In contrast to traditional coupling methods that usually
functionalise lysine or cysteine residues using thermochemically initiated reactions, photochemical reactions occur at room temperature with greatly enhanced kinetics (estimates indicate upwards of three-orders of magnitude faster than standard approaches).
The speed of photochemical reactions means the photoradiochemical approach can
produce fully formulated radiolabelled antibodies from the native protein source in
<10 minutes. In addition, we found that, unlike traditional conjugation chemistries, this
photoradiochemical method is compatible with standard clinical formulations of many
antibodies. This discovery circumvents the need to pre-purify the protein from a GMPgrade source. Further development is required before photoradiochemical methods can
be translated to a clinical setting, but if the two examples highlighted in this section can
be combined,
89
Zr-based radiopharmaceuticals will have a bright future.
5
OO
OO
H
O
N
O
N
HO
photoradiolabelling
<10 min., pH~8
O
UV light ~365 nm
N
H
O
O
Lys
N
H
N
N
N
O
4
H
[89Zr]ZrDFO-azepin-trastuzumab
O
N
OH
O
N
N
H
3
DFO-ArN
O
N
H
O
H
N
N
OOH
3
Scheme 11.4 Illustration of the concept of the simultaneous, one-pot photoradio-
chemical conjugation and labelling of antibodies.
J.P.H. the Swiss National Science Foundation (SNSF Professorship PP00P2_163683 and
PP00P2_190093), the Swiss Cancer League (Krebsliga Schweiz; KLS-4257-08-2017), and the
University of Zurich (UZH) for nancial support. This project has received funding from the
Chapter 11: The Radiochemistry ofZirconium 365
European Union’s Horizon 2020 research and innovation programme/from the European
Research Council under the Grant Agreement No 676904, ERC-StG-2015, NanoSCAN.
REFERENCES
1. Cotton, F.A. and Wilkinson, G. (1972). Advanced Inorganic Chemistry: A Comprehensive
Tex t . Wiley.
2. Earnshaw, A. and Greenwood, N. (1997). Chemistry of the Elements, 2e. Elsevier.
3. van Arkel, A.E. and de Boer, J.H. (1925). Darstellung von reinem Titanium-,
Zirkonium-, Hafnium- und Thoriummetall. Z. Anorg. Allg. Chem.: 345–350.
4. Arnold, R., Augier, C., Baker, J. etal. (1999). Double beta decay of
5. Dokania, N., Degering, D., Lehnert, B. etal. (2018). An improved half-life limit of the
double beta decay of
94
Zr into the excited state of 94Mo. J. Phys. G: Nucl. Part. Phys. 45
(7): 75104.
6. Collier, T.L., Dahl, K., Stephenson, N.A. etal. (2018). Recent applications of a single
quadrupole mass spectrometer in
11
C, 18F and radiometal chemistry. J. Fluorine Chem.
210: 46–55.
7. Busse, S., Brockmann, J., and Rösch, F. (2002). Radiochemical separation of nocarrier-added radioniobium from zirconium targets for application of
compounds. Radiochim. Acta 90 (37438): 411–415.
8. Radchenko, V., Filosofov, D.V., Bochko, O.K. etal. (2014). Separation of
conium target for application in immuno-pet. Radiochim. Acta 102 (5): 433–442.
9. Radchenko, V., Hauser, H., Eisenhut, M. etal. (2012).
90
Nb–a potential PET nuclide:
production and labeling of monoclonal antibodies. Radiochim. Acta 100 (11): 857–863.
10. Holland, J.P., Williamson, M.J., and Lewis, J.S. (2010). Unconventional nuclides for
radiopharmaceuticals. Mol. Imaging 9 (1): 1–10.
11. van Dongen, G.A.M.S., Visser, G.W.M., Lub-de Hooge, M.N. etal. (2007). Immuno-PET:
a navigator in monoclonal antibody development and applications. Oncologist 12 (12):
1379–1389.
12. Deri, M.A., Zeglis, B.M., Francesconi, L.C., and Lewis, J.S. (2013). PET imaging with
89
Zr: from radiochemistry to the clinic. Nucl. Med. Biol. 40 (1): 3–14.
13. Zeglis, B.M., Houghton, J.L., Evans, M.J. etal. (2014). Underscoring the inuence of
inorganic chemistry on nuclear imaging with radiometals. Inorg. Chem. 53: 1880–1899.
14. Zhang, Y., Hong, H., and Cai, W. (2011). PET tracers based on zirconium-89. Cu rr.
Radiopharm. 4: 131–139.
15. Van De Watering, F.C.J., Rijpkema, M., Perk, L. etal. (2014). Zirconium-89 labeled
antibodies: a new tool for molecular imaging in cancer patients. Biomed. Res. Int.
16. Vugts, D.J., Visser, G.W., and van Dongen, G.A. (2013).
89
Zr-PET radiochemistry in the
development and application of therapeutic monoclonal antibodies and other biologicals. Curr. Top. Med. Chem. 13: 446–457.
17. Heskamp, S., Raavé, R., Boerman, O. etal. (2017).
tomography in oncology: state-of-the-art
89
Zr-immuno-positron emission
89
Zr radiochemistry. Bioconjugate Chem. 28
(9): 2211–2223.
96
Zr. Nucl. Phys. A.
90
Nb-labelled
90
Nb from zir-
366 Handbook of Radiopharmaceuticals
18. Fischer, G., Seibold, U., Schirrmacher, R. etal. (2013). 89Zr, a radiometal nuclide with
high potential for molecular imaging with pet: chemistry, applications and remaining
challenges. Molecules 18 (6): 6469–6490.
19. Bhatt, N.B., Pandya, D.N., and Wadas, T.J. (2018). Recent advances in zirconium-89
chelator development. Molecules 23 (3): 638.
20. Dilworth, J.R. and Pascu, S.I. (2018). The chemistry of PET imaging with zirconium-89.
Chem. Soc. Rev. 47 (8): 2554–2571.
21. Schubert, J. (1947). Treatment of plutonium poisoning by metal displacement. Science
105 (2728): 389–390.
22. Dobson, E.L. and Gofman, J.W. (1949). Studies with colloids containing radioisotopes
of yttrium, zirconium, columbium, and lanthanum; the controlled selective localization of radioisotopes of yttrium, zirconium, and columbium in the bone marrow, liver,
and spleen. J. Lab. Clin. Med. 34 (3): 305–312.
23. Mealey, J.J. (1957). Turn-over of carrier-free zirconium-89 in man. Nature
179: 673–674.
24. Shure, K. and Deutsch, M. (1951). Radiations from Zr
89
. Physiol. Rev. 82 (122): 948.
25. Inarida, M. and Shimamura, A. (1970). Separation of carrier-free zirconium from
yttrium target. Rikagaku Kenkyusho Hokoku 46: 63–65.
26. Link, J., Krohn, K., Eary, J. etal. (1986).
89
Zr for antibody labeling and positron
emission tomography. J. Labelled Compd. Radiopharm. 23: 1296–1297.
27. Dejesus, O.T. and Nickles, R.J. (1990). Production and purication of
89
Zr, a potential
PET antibody label. Int. J. Radiat. Appl. Instrum. Part A 41 (8): 789–790.
28. Lahiri, S., Mukhopadhyay, B., and Das, N.R. (1997). Simultaneous production of
90,91m,92m
and
Nb in α-particle activated yttrium and their subsequent separation by
89
Zr
HDEHP. Appl. Radiat. Isot. 48 (7): 883–886.
29. Kandil, S.A., Spahn, I., Scholten, B. etal. (2007). Excitation functions of (α,xn)
reactions on
87
Y, 88Y and 89Zr. Appl. Radiat. Isot. 65 (5): 561–568.
nat
Rb and
nat
Sr from threshold up to 26 MeV: possibility of production of
30. Zweit, J., Downey, S., and Sharma, H.L. (1991). Production of no-carrier-added zirconium-89 for positron emission tomography. Int. J. Radiat. Appl. Instrum. Part A 42
(2): 199–201.
31. Omara, H.M., Hassan, K.F., Kandil, S.A. etal. (2009). Proton induced reactions on
89
Y with particular reference to the production of the medically interesting radionu-
89
clide
Zr. Radiochim. Acta 97 (9): 467–471.
32. Taghilo, M. (2012). Cyclotron production of
89
Zr: a potent radionuclide for positron
emission tomography. Int. J. Phys. Sci. 7 (14): 1321–1325.
33. Kandil, S.A., Scholten, B., Saleh, Z.A. etal. (2007). A comparative study on the separation of radiozirconium via ion-exchange and solvent extraction techniques, with
particular reference to the production of
88
Zr and 89Zr in proton induced reactions on
yttrium. J. Radioanal. Nucl. Chem. 274 (1): 45–52.
34. Meijs, W.E., Herscheid, J.D.M., Haisma, H.J., and Pinedo, H.M. (1992). Evaluation
of desferal as a bifunctional chelating agent for labeling antibodies with Zr-89.
Int. J. Radiat. Appl. Instrum. Part A.
Chapter 11: The Radiochemistry ofZirconium 367
35. Meijs, W.E., Herscheid, J.D.M., Haisma, H.J. etal. (1994). Production of highly pure
no-carrier added
89
Zr for the labelling of antibodies with a positron emitter. Appl.
Radiat. Isot.
36. Meijs, W.E., Haisma, H.J., Klok, R.P. etal. (1997). Zirconium-labeled monoclonal
antibodies and their distribution in tumor-bearing nude mice. J. Nucl. Med.
37. Verel, I., Visser, G.W.M., Boellaard, R. etal. (2003).
procedures for the production of
89
Zr-labeled monoclonal antibodies. J. Nucl. Med. 44
89
Zr immuno-PET: comprehensive
(8): 1271–1281.
38. Verel, I., Visser, G.W.M., Boerman, O.C. etal. (2003). Long-lived positron emitters zirconium-89 and iodine-124 for scouting of therapeutic radioimmunoconjugates with
PET. Cancer Biother. Radiopharm. 18 (4): 655–661.
39. Holland, J.P., Sheh, Y., and Lewis, J.S. (2009). Standardized methods for the production of high specic-activity zirconium-89. Nucl. Med. Biol. 36 (7): 729–739.
40. Pandey, M.K., Engelbrecht, H.P., Byrne, J.P. etal. (2014). Production of
89
Y(p,n)89Zr reaction in aqueous solution: eect of solution composition on in-target
89
Zr via the
chemistry. Nucl. Med. Biol. 41 (4): 309–316.
41. Pandey, M.K., Bansal, A., Engelbrecht, H.P. etal. (2016). Improved production and
processing of
89
Zr using a solution target. Nucl. Med. Biol. 43 (1): 97–100.
42. Link, J.M., Krohn, K.A., and O’Hara, M.J. (2017). A simple thick target for production
89
of
Zr using an 11 MeV cyclotron. Appl. Radiat. Isot. 122: 211–214.
43. Alnahwi, A., Tremblay, S., and Guérin, B. (2018). Comparative study with
89
Y-pressed targets for the production of 89Zr. Appl. Sci. 8 (9): 1579.
89
Y-foil and
44. Carter, L.M., Poty, S., Sharma, S.K., and Lewis, J.S. (2018). Preclinical optimization of antibody-based radiopharmaceuticals for cancer imaging and radionuclide
therapy–model, vector, and radionuclide selection. J. Labelled Compd. Radiopharm.
61 (9): 611–635.
45. Holland, J.P. (2018). Chemical kinetics of radiolabelling reactions. Chem. Eur. J. In press.
46. Kobayashi, T., Sasaki, T., Takagi, I., and Moriyama, H. (2009). Zirconium solubility in
ternary aqueous system of Zr(IV)-OH-carboxylates. J. Nucl. Sci. Technol. 46 (2): 142–148.
47. Kobayashi, T., Sasaki, T., Takagi, I., and Moriyama, H. (2007). Solubility of zirconium
(IV) hydrous oxides. J. Nucl. Sci. Technol. 44: 90–94.
48. Sasaki, T., Kobayashi, T., Takagi, I., and Moriyama, H. (2008). Hydrolysis constant and
coordination geometry of zirconium(IV). J. Nucl. Sci. Technol. 45 (8): 735–739.
49. Davydov, Y.P., Davydov, D.Y., and Zemskova, L.M. (2006). Speciation of Zr(IV) radionuclides in solutions. Radiochemistry 48 (4): 358–364.
50. Baggio, R., Garland, M.T., and Perec, M. (1997). A binuclear zirconium(IV) oxalate
complex with a μ-oxalate coordination mode. Crystal structure of K
C
)]4H2O. Inorg. Chem. 36 (14): 3198–3200.
2O4
[{Zr(C2O4)3}2(μ-
6
51. Abou, D.S., Ku, T., and Smith-Jones, P.M. (2011). In vivo biodistribution and
accumulation of
89
Zr in mice. Nucl. Med. Biol. 38 (5): 675–681.
52. Graves, S.A., Kutyre, C., Barrett, K.E. etal. (2018). Evaluation of a chloride-based
89
Zr isolation strategy using a tributyl phosphate (TBP)-functionalized extraction
resin. Nucl. Med. Biol. 64–65: 1–7.
Handbook of Radiopharmaceuticals
53. Holland, J.P., Divilov, V., Bander, N.H. etal. (2010). 89Zr-DFO-J591 for immunoPET
of prostate-specic membrane antigen expression in vivo. J. Nucl. Med. 51 (8):
1293–1300.
54. Guérard, F., Lee, Y.S., Tripier, R. etal. (2013). Investigation of Zr(IV) and
89
Zr(IV) complexation with hydroxamates: progress towards designing a better chelator than desferrioxamine B for immuno-PET imaging. Chem. Commun. 49 (10): 1002–1004.
55. Holland, J.P. and Vasdev, N. (2014). Charting the mechanism and reactivity of zirconium oxalate with hydroxamate ligands using density functional theory: implications
in new chelate design. Dalton Trans. 43 (26): 9872–9884.
56. Patra, M., Bauman, A., Mari, C. etal. (2014). An octadentate bifunctional chelating
agent for the development of stable zirconium-89 based molecular imaging probes.
Chem. Commun. 50 (78): 11523–11525.
57. Vugts, D.J., Klaver, C., Sewing, C. etal. (2017). Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional
chelator DFO-pPhe-NCS for
89
Zr-immuno-PET. Eur. J. Nucl. Med. Mol. Imaging 44
(2): 286–295.
58. Pandya, D.N., Bhatt, N., Yuan, H. etal. (2017). Zirconium tetraazamacrocycle
complexes display extraordinary stability and provide a new strategy for zirconium89-based radiopharmaceutical development. Chem. Sci. 8 (3): 2309–2314.
59. Tieu, W., Lifa, T., Katsis, A., and Codd, R. (2017). Octadentate zirconium(IV)-loaded
macrocycles with varied stoichiometry assembled from hydroxamic acid monomers
using metal-templated synthesis. Inorg. Chem. 56 (6): 3719–3728.
60. Tinianow, J.N., Pandya, D.N., Pailloux, S.L. etal. (2016). Evaluation of a 3-hydroxypyridin-2-one (2,3-HOPO) based macrocyclic chelator for
89Zr4+
and its use for immunoPET imaging of HER2 positive model of ovarian carcinoma in mice. Theranostics
6 (4): 511–521.
61. Deri, M.A., Ponnala, S., Zeglis, B.M. etal. (2014). Alternative chelator for
89
Zr radio-
pharmaceuticals: radiolabeling and evaluation of 3,4,3-(LI-1,2-HOPO). J. Med. Chem.
57 (11): 4849–4860.
62. Deri, M.A., Ponnala, S., Kozlowski, P. etal. (2015). P-SCN-Bn-HOPO: a superior bifunctional chelator for
89
Zr immunoPET. Bioconjugate Chem. 26 (12): 2579–2591.
63. Rudd, S.E., Roselt, P., Cullinane, C. etal. (2016). A desferrioxamine B squaramide
ester for the incorporation of zirconium-89 into antibodies. Chem. Commun. 52 (80):
11889 –11892.
64. Boros, E., Holland, J.P., Kenton, N. etal. (2016). Macrocycle-based hydroxamate
ligands for complexation and immunoconjugation of
89
Zirconium for positron
emission tomography (PET) imaging. ChemPlusChem 81 (3): 274–281.
65. Briand, M., Aulsebrook, M.L., Mindt, T.L., and Gasser, G. (2017). A solid phase-assisted
approach for the facile synthesis of a highly water-soluble zirconium-89 chelator for
radiopharmaceutical development. Dalton Trans. 46 (47): 16387–16389.
66. Adams, C.J., Wilson, J.J., and Boros, E. (2017). Multifunctional desferrichrome ana-
logues as versatile
89
Zr(IV) chelators for immunoPET probe development. Mol. Phar-
maceutics 14 (8): 2831–2842.
Chapter 11: The Radiochemistry ofZirconium
67. Bhatt, N.B., Pandya, D.N., Xu, J. etal. (2017). Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89. PLoS One 12 (6): 1–13.
68. Pandya, D.N., Pailloux, S., Tatum, D. etal. (2015). Di-macrocyclic terephthalamide
ligands as chelators for the PET radionuclide zirconium-89. Chem. Commun. 51 (12):
2301–2303.
69. Vosjan, M.J.W.D., Perk, L.R., Visser, G.W.M. etal. (2010). Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. Nat. Protoc. 5 (4): 739–743.
70. Vugts, D.J., Vervoort, A., Stigter-Van Walsum, M. etal. (2011). Synthesis of phosphine
and antibody-azide probes for in vivo staudinger ligation in a pretargeted imaging
and therapy approach. Bioconjugate Chem. 22 (10): 2072–2081.
71. Zeglis, B.M., Davis, C.B., Aggeler, R. etal. (2013). Enzyme-mediated methodology for
the site-specic radiolabeling of antibodies based on catalyst-free click chemistry.
Bioconjugate Chem. 24 (6): 1057–1067.
72. Zeglis, B.M., Mohindra, P., Weissmann, G.I. etal. (2011). Modular strategy for the
construction of radiometalated antibodies for positron emission tomography based on
inverse electron demand diels-alder click chemistry. Bioconjugate Chem. 22 (10): 2048–2059.
73. Houghton, J.L., Zeglis, B.M., Abdel-Atti, D. etal. (2016). Pretargeted immuno-PET
of pancreatic cancer: overcoming circulating antigen and internalized antibody to
reduce radiation doses. J. Nucl. Med. 57 (3): 453–459.
74. Wright, B.D., Whittenberg, J., Desai, A. etal. (2016). Microuidic preparation of a
89
Zr-labeled trastuzumab single-patient dose. J. Nucl. Med. 57 (5): 747–752.
75. Perk, L.R., Visser, O.J., Stigter-Van Walsum, M. etal. (2006). Preparation and evaluation of
89
Zr-Zevalin for monitoring of 90Y-Zevalin biodistribution with positron
emission tomography. Eur. J. Nucl. Med. Mol. Imaging 33 (11): 1337–1345.
76. Börjesson, P.K.E., Jauw, Y.W.S., Boellaard, R. etal. (2006). Performance of immunopositron emission tomography with zirconium-89-labeled chimeric monoclonal
antibody U36 in the detection of lymph node metastases in head and neck cancer
patients. Clin. Cancer Res. 12 (7): 2133–2140.
77. Perk, L.R., Stigter-Van Walsum, M., Visser, G.W.M. etal. (2008). Quantitative PET
imaging of Met-expressing human cancer xenografts with
89
Zr-labelled monoclonal
antibody DN30. Eur. J. Nucl. Med. Mol. Imaging 35 (10): 1857–1867.
78. Dijkers, E.C.F., Kosterink, J.G.W., Rademaker, A.P. etal. (2009). Development and characterization of clinical-grade
89
Zr-trastuzumab for HER2/neu immunoPET imaging.
J. Nucl. Med. 50 (6): 974–981.
79. Holland, J.P., Caldas-Lopes, E., Divilov, V. etal. (2010). Measuring the pharmacodynamic eects of a novel Hsp90 inhibitor on HER2/neu expression in mice using
89
Zr-DFO-trastuzumab. PLoS One: 5, e8859–1.
80. Chang, A.J., DeSilva, R., Jain, S. etal. (2012).
89
Zr-radiolabeled trastuzumab imaging in
orthotopic and metastatic breast tumors. Pharmaceuticals 5 (1): 79–93.
81. Janjigian, Y.Y., Viola-Villegas, N., Holland, J.P. etal. (2013). Monitoring afatinib
treatment in HER2-positive gastric cancer with
18
F-FDG and 89Zr-trastuzumab PET.
J. Nucl. Med. 54 (6): 936–943.
370 Handbook of Radiopharmaceuticals
82. Oude Munnink, T.H., de Korte, M.A., Nagengast, W.B. etal. (2010). 89Zr-trastuzumab
PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human
tumour xenograft. Eur. J. Cancer 46 (3): 678–684.
83. Oude Munnink, T.H., De Vries, E.G.E., Vedelaar, S.R. etal. (2012). Lapatinib and 17AAG
reduce
89
Zr-trastuzumab-F(ab’) 2 uptake in SKBR3 tumor xenografts. Mol. Pharmaceu-
tics 9 (11): 2995–3002.
84. Aerts, H.J.W.L., Dubois, L., Perk, L. etal. (2008). Disparity between in vivo EGFR
expression and 89Zr-labeled cetuximab uptake assessed with PET. J. Nucl. Med. 50
(1): 123–131.
85. Perk, L.R., Visser, G.W.M., Vosjan, M.J.W.D. etal. (2005).
isotope for scouting biodistribution of the therapeutic radiometals
89
Zr as a PET surrogate radio-
90
Y and
177
Lu in
tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
J. Nucl. Med. 46 (11): 1898–1906.
86. Holland, J.P., Evans, M.J., Rice, S.L. etal. (2012). Annotating MYC status with
89
Zr-transferrin imaging. Nat. Med. 18 (10): 1586–1591.
87. Evans, M.J., Holland, J.P., Rice, S.L. etal. (2013). Imaging tumor burden in the brain
89
with
Zr-transferrin. J. Nucl. Med. 54 (1): 90–95.
88. Doran, M.G., Carnazza, K.E., Steckler, J.M. etal. (2016). Applying
89
Zr-transferrin to
study the pharmacology of inhibitors to BET bromodomain containing proteins.
Mol. Pharmaceutics 13 (2): 683–688.
89. Aggarwal, R., Behr, S.C., Paris, P.L. etal. (2017). Real-time transferrin-based PET
detects MYC-positive prostate cancer. Mol. Cancer Res. 15 (9): 1221–1229.
90. Henry, K.E., Dilling, T.R., Abdel-Atti, D. etal. (2017). Non-invasive
shows improved tumor targeting compared to
18
F-FDG PET in MYC-overexpressing
89
Zr-transferrin PET
human triple negative breast cancer. J. Nucl. Med. jnumed.117.192286.
91. Ruggiero, A., Holland, J.P., Hudolin, T. etal. (2011). Targeting the internal epitope of
prostate-specic membrane antigen with
89
Zr-7E11 immuno-PET. J. Nucl. Med. 52 (10):
1608–1615.
92. Rylova, S.N., Del Pozzo, L., Klingeberg, C. etal. (2016). Immuno-PET imaging of CD30-
positive lymphoma using
89
Zr-desferrioxamine-labeled CD30-specic AC-10 antibody.
J. Nucl. Med. 57 (1): 96–102.
93. Viola-Villegas, N.T., Sevak, K.K., Carlin, S.D. etal. (2014). Noninvasive imaging of
PSMA in prostate tumors with89Zr-labeled huJ591 engineered antibody fragments:
the faster alternatives. Mol. Pharmaceutics 11 (11): 3965–3973.
94. Oude Munnink, T.H., Tamas, K.R., Lub-de Hooge, M.N. etal. (2013). Placental growth
factor (PlGF)-specic uptake in tumor microenvironment of
89
Zr-labeled PlGF anti-
body RO5323441. J. Nucl. Med. 54 (6): 929–935.
95. Nagengast, W.B., de Vries, E.G., Hospers, G.A. etal. (2007). In vivo VEGF imaging with
radiolabeled bevacizumab in a human ovarian tumor xenograft. J. Nucl. Med. 48 (8):
1313–1319.
96. Nagengast, W.B., de Korte, M.A., Oude Munnink, T.H. etal. (2010).
89
Zr-bevacizumab
PET of early antiangiogenic tumor response to treatment with HSP90 inhibitor NVPAUY922. J. Nucl. Med. 51 (5): 761–767.
Chapter 11: The Radiochemistry ofZirconium 371
97. Nagengast, W.B., Lub-de Hooge, M.N., Oosting, S.F. etal. (2011). VEGF-PET imaging
is a noninvasive biomarker showing dierential changes in the tumor during
sunitinib treatment. Cancer Res. 71 (1): 143–153.
98. Natarajan, A., Habte, F., and Gambhir, S.S. (2012). Development of a novel long-lived
immunoPET tracer for monitoring lymphoma therapy in a humanized transgenic
mouse model. Bioconjugate Chem. 23 (6): 1221–1229.
99. Hoeben, B.A.W., Kaanders, J.H.A.M., Franssen, G.M. etal. (2010). PET of hypoxia with
89
Zr-labeled cG250-F(ab’)2 in head and neck tumors. J. Nucl. Med. 51 (7):
1076–1083.
100. Stillebroer, A.B., Franssen, G.M., Mulders, P.F.A. etal. (2013). ImmunoPET imaging
of renal cell carcinoma with
124
I- and 89Zr-labeled anti-CAIX monoclonal antibody
cG250 in mice. Cancer Biother. Radiopharm. 28 (7): 510–515.
101. Hong, H., Zhang, Y., Severin, G.W. etal. (2012). Multimodality imaging of breast
cancer experimental lung metastasis with bioluminescence and a monoclonal
antibody dual-labeled with
89
Zr and IRDye 800CW. Mol. Pharmaceutics 9 (8):
2339–2349.
102. Heskamp, S., van Laarhoven, H.W.M., Molkenboer-Kuenen, J.D.M. etal. (2010).
ImmunoSPECT and immunoPET of IGF-1R expression with the radiolabeled
antibody R1507 in a triple-negative breast cancer model. J. Nucl. Med. 51 (10):
1565–1572.
103. Jagoda, E.M., Lang, L., Bhadrasetty, V. etal. (2012). Immuno-PET of the hepatocyte
growth factor receptor met using the 1-armed antibody onartuzumab. J. Nucl. Med.
53 (10): 1592–1600.
104. Sugyo, A., Tsuji, A.B., Sudo, H. etal. (2013). Evaluation of
89
Zr-labeled human antiCD147 monoclonal antibody as a positron emission tomography probe in a mouse
model of pancreatic cancer. PLoS One 8 (4).
105. Bhattacharyya, S., Kurdziel, K., Wei, L. etal. (2013). Zirconium-89 labeled panitumumab: a potential immuno-PET probe for HER1-expressing carcinomas. Nucl. Med.
Biol. 40 (4): 451–457.
106. Wei, L., Shi, J., Afari, G., and Bhattacharyya, S. (2014). Preparation of clinical-grade
89Zr-panitumumab as a positron emission tomography biomarker for evaluating
epidermal growth factor receptor-targeted therapy. J. Labelled Compd. Radiopharm.
57 (1): 25–35.
107. Vugts, D.J., Heuveling, D.A., Stigter-van Walsum, M. etal. (2014). Preclinical evaluation of
89
Zr-labeled anti-CD44 monoclonal antibody RG7356 in mice and cyno-
molgus monkeys: prelude to phase 1 clinical studies. MAbs 6 (2): 567–575.
108. Sham, J.G., Kievit, F.M., Grierson, J.R. etal. (2014). Glypican-3-targeted
89
Zr PET
imaging of hepatocellular carcinoma. J. Nucl. Med. 55 (5): 799–804.
109. ter Weele, E.J., van Scheltinga, A.G.T.T., Kosterink, J.G.W. etal. (2015). Imaging the
distribution of an antibody-drug conjugate constituent targeting mesothelin with
89
Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts. Onco-
target 6 (39).
110. Rizvi, S.N.F., Visser, O.J., Vosjan, M.J.W.D. etal. (2012). Biodistribution, radiation
dosimetry and scouting of
90
Y-ibritumomab tiuxetan therapy in patients with
372 Handbook of Radiopharmaceuticals
relapsed B-cell non-Hodgkin’s lymphoma using 89Zr-ibritumomab tiuxetan and PET.
Eur. J. Nucl. Med. Mol. Imaging 39 (3): 512–520.
111. Borjesson, P.K.E., Jauw, Y.W.S., de Bree, R. etal. (2009). Radiation dosimetry of
89
Zr-labeled chimeric monoclonal antibody U36 as used for immuno-PET in head and
neck cancer patients. J. Nucl. Med. 50 (11): 1828–1836.
112. Dijkers, E., Lub-de Hooge, M.N., Kosterink, J.G. etal. (2007). Characterization
89
of
Zr-trastuzumab for clinical HER2 immunoPET imaging. J. Clin. Oncol. 25
(18_suppl): 3508.
113. Dijkers, E.C., Oude Munnink, T.H., Kosterink, J.G. etal. (2010). Biodistribution of
89
Zr-trastuzumab and PET imaging of HER2-positive lesions in patients with meta-
static breast cancer. Clin. Pharmacol. Ther. 87 (5): 586–592.
114. Laforest, R., Lapi, S.E., Oyama, R. etal. (2016). [
89
Zr]Trastuzumab: evaluation of
radiation dosimetry, safety, and optimal imaging parameters in women with HER2positive breast cancer. Mol. Imaging Biol. 18 (6): 952–959.
115. O’Donoghue, J.A., Lewis, J.S., Pandit-Taskar, N. etal. (2017). Pharmacokinetics, biodistribution, and radiation dosimetry for
89
Zr-trastuzumab in patients with esopha-
gogastric cancer. J. Nucl. Med. jnumed.117.194555.
116. Morris, M.J., Pandit-Taskar, N., Carrasquillo, J.A. etal. (2013). Phase I trial of zirco-
nium 89 (Zr
89
) radiolabeled J591 in metastatic castration-resistant prostate cancer
(mCRPC). J. Clin. Oncol. 31 (6).
117. Pandit-Taskar, N., O’Donoghue, J.A., Beylergil, V. etal. (2014).
89
Zr-huJ591 immuno-
PET imaging in patients with advanced metastatic prostate cancer. Eur. J. Nucl. Med.
Mol. Imaging 41: 2093–2105.
118. Pandit-Taskar, N., O’Donoghue, J.A., Durack, J.C. etal. (2015). A phase I/II study for
analytic validation of
89
Zr-J591 immunoPET as a molecular imaging agent for meta-
static prostate cancer. Clin. Cancer Res. 21 (23): 5277–5285.
119. Pandit-Taskar, N., Veach, D.R., Fox, J.J. etal. (2016). Evaluation of castrationresistant prostate cancer with androgen receptor-axis imaging. J. Nucl. Med. 57
(Supplement_3): 73S–78S.
120. Pandit-Taskar, N., ODonoghue, J.A., Ruan, S. etal. (2016). First-in-human imaging
89
with
Zr-Df-IAB2M anti-PSMA minibody in patients with metastatic prostate cancer: pharmacokinetics, biodistribution, dosimetry, and lesion uptake. J. Nucl. Med.
57 (12): 1858–1864.
121. Lindenberg, L., Adler, S., Turkbey, I.B. etal. (2017). Dosimetry and rst human experience with (89)Zr-panitumumab. Am. J. Nucl. Med. Mol. Imaging 7 (4): 195–203.
122. Van Der Bilt, A.R.M., AGT, T.V.S., Timmer-Bosscha, H. etal. (2012). Measurement of
tumor VEGF-A levels with
89
Zr-bevacizumab PET as an early biomarker for the antiangiogenic eect of everolimus treatment in an ovarian cancer xenograft model.
Clin. Cancer Res. 18 (22): 6306–6314.
123. Gaykema, S.B.M., Brouwers, A.H., Lub-de Hooge, M.N. etal. (2013).
89
Zr-bevaci-
zumab PET imaging in primary breast cancer. J. Nucl. Med. 54 (7): 1014–1018.
124. van Asselt, S.J., Oosting, S.F., Brouwers, A.H. etal. (2014). Everolimus
reduces
89
Zr-bevacizumab tumor uptake in patients with neuroendocrine tumors.
J. Nucl. Med. 55 (7): 1087–1092.
Chapter 11: The Radiochemistry ofZirconium 373
125. Oosting, S.F., Brouwers, A.H., van Es, S.C. etal. (2015). 89Zr-bevacizumab PET
visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and dierential eects of antiangiogenic treatment. J. Nucl. Med. 56
(1): 63–69.
126. den Hollander, M.W., Bensch, F., Glaudemans, A.W.J.M. etal. (2015). TGF-antibody
uptake in recurrent high-grade glioma imaged with
89
Zr-fresolimumab PET. J. Nucl.
Med. 56 (9): 1310–1314.
127. Muylle, K., Flamen, P., Vugts, D.J. etal. (2015). Tumour targeting and radiation dose
of radioimmunotherapy with
89
by
Zr-rituximab immuno-PET: impact of preloading with unlabelled rituximab. Eur.
90
Y-rituximab in CD20+ B-cell lymphoma as predicted
J. Nucl. Med. Mol. Imaging 42 (8): 1304–1314.
128. van Der Houven, W.M., Van Oordt, C., Gootjes, E.C. etal. (2015). Zr-cetuximab PET
imaging in patients with advanced colorectal cancer. Oncotarget 6 (30).
129. Jauw, Y.W., Menke-van der Houven van Oordt, C.W., Hoekstra, O.S. etal. (2016).
Immuno-positron emission tomography with zirconium-89-labeled monoclonal antibodies in oncology: what can we learn from initial clinical trials? Front.
Pharmacol. 7: 131.
130. Bensch, F., Smeenk, M.M., van Es, S.C. etal. (2018). Comparative biodistribution
analysis across four dierent
89
Zr-monoclonal antibody tracers-the rst step
towards an imaging warehouse. Theranostics 8 (16): 4295–4304.
131. Makris, N.E., Boellaard, R., Visser, E.P. etal. (2014). Multicenter harmonization of
89
Zr PET/CT performance. J. Nucl. Med. 55 (2): 264–267.
132. Patra, M., Eichenberger, L.S., Fischer, G., and Holland, J.P. (2019). Radiochemistry
in a ash: photochemical conjugation and one-pot radiolabelling of antibodies for
immuno-PET. Angew. Chem. Int. Ed. 58: 1928–1933. DOI: 10.1002/anie.20181328.
133. Eichenberger, L.S., Patra, M., and Holland, J.P. (2019). Photoactive chelates for
radiolabelling proteins. Chem. Commun. 55, 2257–2260. DOI: 10.1039/C8CC09660K.
134. Poot, A.J., Adamzek, K.W.A., Windhorst, A.D. etal. (2018). Fully automated zirconium-89 labeling and purication of antibodies. J. Nucl. Med. 60(5):691–695.
374 Handbook of Radiopharmaceuticals